Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment algorithms for hepatitis B and C

E R Schiff1

  • 1University of Miami, School of Medicine, Florida.

Gut
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Predictors for successful chronic hepatitis B treatment are known, but not for chronic hepatitis C. This complexity impacts treatment guidelines and future clinical strategies for both viral hepatitis types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease.

Human genetics·2018
Same author

Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection.

Journal of viral hepatitis·2015
Same author

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Journal of viral hepatitis·2013
Same author

Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2010
Same author

Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C.

Alimentary pharmacology & therapeutics·2010
Same author

Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome.

Transplantation proceedings·2008
Same journal

USP20 promotes CD8<sup>+</sup> T cell exhaustion and impairs KRAS<sup>G12D</sup> inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.

Gut·2026
Same journal

CTCF-rs705704-SUOX axis is important for the association between hypothyroidism and metabolic dysfunction-associated steatotic liver disease.

Gut·2026
Same journal

<i>Helicobacter pylori</i> infection, treatment and colorectal cancer risk by genetic predisposition: evidence from two randomised trials.

Gut·2026
Same journal

Correction: Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.

Gut·2026
Same journal

Correction: Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.

Gut·2026
Same journal

Cancer risk in autoimmune gastritis: perspectives from a Chinese cohort.

Gut·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Chronic hepatitis B (CHB) treatment response predictors are established.
  • Chronic hepatitis C (CHC) lacks consistently demonstrable treatment response predictors.
  • This disparity complicates CHC treatment guidelines compared to CHB.

Purpose of the Study:

  • To outline current treatment options for CHB and CHC.
  • To compare the complexity of treatment guidelines for CHB and CHC.
  • To speculate on future clinical challenges in managing viral hepatitis.

Main Methods:

  • Review of existing literature on CHB and CHC treatment.
  • Comparative analysis of treatment guidelines and response predictors.
  • Discussion of clinical management strategies and future outlook.

Related Experiment Videos

Main Results:

  • Identified several predictors for early and sustained response in CHB treatment.
  • Confirmed the absence of consistently demonstrable predictors for CHC treatment response.
  • Highlighted the increased complexity of CHC treatment guidelines.

Conclusions:

  • Treatment strategies for CHB are more defined due to known predictors.
  • CHC management requires more complex approaches owing to unpredictable treatment responses.
  • Future clinical practice will need to address evolving challenges in viral hepatitis therapy.